Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAG-GO for Persistent, Relapsed or Refractory Acute Myeloid Leukemia
NCT04050280Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2019
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by University of Maryland, Baltimore. Started Nov 2019; status: recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04050280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050280.